Beijing Double Heron Pharmaceutical Co., Ltd. is mainly engaged in pharmaceutical research and development of genetic engineering, production and management. Its predecessor was established in December 1994, "Biotechnology Co., Ltd. Beijing Egret Park." 7, 1998, the company also changed its name to "Beijing Double Heron Pharmaceutical Co., Ltd.", August 2000, the company incorporated company restructuring. September 2004, the "double Heron Pharmaceutical" stock (code 002038) listed on the Shenzhen Stock Exchange grand.

Since its establishment, always adhering to the "quality of survival, innovation and development "business philosophy, 10 years, research and development and on the market with independent intellectual property rights of a class of drugs 2 countries and 8 countries, two types of drugs. Meanwhile, there are nearly 20 independent national commitment, the second category to the new drug is in clinical testing laboratory research and development or reporting of different stages of production, the next two years, the company will have dozens of new products have on the market. Some research and development projects in Beijing and has won several national scientific and technological progress second prize.

company in 1997, 2000 and 2002, has four time as a business and applying for and won the national "863" Project Fund, two projects funded by the National Technology Innovation Fund. October 1996, was identified as high-tech enterprises of Beijing Science and Technology Commission, Beijing, 1999, major support was included in the enterprise, the field of bio-pharmaceutical enterprises. 2000, 2003 and 2004, all three formulations have the entire company through the National Drugs and Drug Administration of China Quality Certification (GMP). July 2000 organized by the Ministry of Science and Chinese Academy of Sciences of the high-tech enterprises (double high-identified), is a 4 "863" program outcome of the industrial base.